MySheen

South Korean scientists have bred "biochemical pigs" to produce therapeutic agents for cerebral thrombosis.

Published: 2024-11-05 Author: mysheen
Last Updated: 2024/11/05, South Korean scientists have successfully developed a biochemical pig (biopig) that produces a therapeutic agent for cerebral thrombosis (cerebral hemorrhage) through urine. South Korea's Rural Revitalization Agency said a few days ago: "the gene for the treatment of cerebral thrombosis (TPA) was injected into the fertilized eggs of pigs and successfully bred four pigs whose therapeutic substances can be excreted through milk and urine." South Korea has become the second country in the world after the United States to produce animals that can be genetically modified to treat cerebral thrombosis. The United States adopted transgenic technology in 1997.

South Korean scientists have successfully developed a biochemical pig (biopig) that produces a therapeutic agent for cerebral thrombosis (cerebral hemorrhage) through urine.

South Korea's Rural Revitalization Agency said a few days ago: "the gene for the treatment of cerebral thrombosis (TPA) was injected into the fertilized eggs of pigs and successfully bred four pigs whose therapeutic substances can be excreted through milk and urine." South Korea has become the second country in the world after the United States to produce animals that can be genetically modified to treat cerebral thrombosis. In 1997, the United States successfully bred a goat that uses milk to produce a therapeutic substance for cerebral thrombosis through transgenic technology.

The price of cerebral thrombus therapeutic agents extracted from organisms is extremely high, up to 53 million won per gram, so the pig will generate at least 200-300 million won a year. In 1998, the bioengineering animal production team of Zhenxing Hall in rural South Korea successfully bred pigs to make therapeutic agents for anemia through transgene.

 
0